Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease
Keywords: autoimmune blistering disease; bullous pemphigoid; epidermolysis bullosa acquisita; rituximabBP, bullous pemphigoid; CP, cicatricial pemphigoid; EBA, epidermolysis bullosa acquisita; IVIG, intravenous immunoglobulin; PV, pemphigus vulgaris